Chemed Corporation (NYSE:CHE) Stock Has Average Price Target of $554.60

Shares of Chemed Corporation (NYSE:CHE) have received a consensus rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $554.60.

Several equities analysts have commented on CHE shares. Wall Street Zen upgraded shares of Chemed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. UBS Group began coverage on shares of Chemed in a research note on Friday, September 25th. They set a “buy” rating and a $650.00 price target on the stock. Finally, Royal Bank Of Canada lifted their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th.

Chemed Trading Down 0.6%

Shares of NYSE:CHE opened at $512.20 on Tuesday. The company has a market cap of $6.69 billion, a PE ratio of 25.73, a P/E/G ratio of 2.06 and a beta of 0.51. The company’s 50 day moving average is $517.57 and its two-hundred day moving average is $471.11. Chemed has a 52 week low of $365.20 and a 52 week high of $557.00. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, topping analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. During the same quarter in the previous year, the firm posted $4.27 earnings per share. The company’s revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Equities analysts predict that Chemed will post 23.55 earnings per share for the current fiscal year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were paid a $0.70 dividend. This is a boost from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a yield of 0.5%. The ex-dividend date was Monday, August 17th. Chemed’s payout ratio is currently 14.06%.

Insiders Place Their Bets

In other Chemed news, Director Patrick Grace sold 190 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director owned 3,533 shares of the company’s stock, valued at approximately $1,879,556. This trade represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin McNamara sold 2,000 shares of Chemed stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total value of $1,079,020.00. Following the transaction, the chief executive officer directly owned 70,418 shares in the company, valued at approximately $37,991,215.18. This trade represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 9,190 shares of company stock valued at $4,833,160. 3.33% of the stock is currently owned by insiders.

Institutional Trading of Chemed

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new position in Chemed during the 2nd quarter worth $1,726,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Chemed during the second quarter worth about $4,413,000. Lone Peak Global Investors LLC boosted its stake in shares of Chemed by 38.1% during the second quarter. Lone Peak Global Investors LLC now owns 37,099 shares of the company’s stock worth $17,279,000 after buying an additional 10,226 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Chemed by 41.7% during the second quarter. Hsbc Holdings PLC now owns 12,346 shares of the company’s stock worth $5,729,000 after buying an additional 3,632 shares during the period. Finally, Amundi grew its holdings in shares of Chemed by 51.5% during the second quarter. Amundi now owns 53,856 shares of the company’s stock worth $25,083,000 after buying an additional 18,301 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.